Curated News
By: NewsRamp Editorial Staff
October 21, 2024
Clene (NASDAQ: CLNN) Participates in Top Investor Conferences to Showcase Lead Drug Candidate CNM-Au8
Discuss on Reddit
LinkedIn
Substack
TelegramTLDR
- Clene presented at two top investor conferences, showcasing the potential of their lead drug candidate, CNM-Au8, for treating ALS and other neurodegenerative conditions.
- Clene's lead drug candidate, CNM-Au8, has shown promise in restoring and protecting neurological function, offering hope for patients with ALS and other conditions.
- Clene's research and drug development have the potential to improve the lives of patients with ALS, MS, and Parkinson's, offering hope for better treatment options.
- Clene seeks accelerated approval for CNM-Au8 for ALS and is scheduled to meet with FDA leadership in November, marking a significant step forward in potential treatment options.
Impact - Why it Matters
This news matters as it highlights the participation of Clene and its subsidiary in important investor conferences to present breakthrough achievements and key updates on their lead drug candidate, offering hope for patients with ALS and other neurodegenerative conditions.
Summary
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., participated in two top investor conferences this month to present its latest achievements and key updates on its lead drug candidate, CNM-Au8. On October 15, the company gave a fireside presentation at the 2024 Maxim Healthcare Virtual Summit. The October 15-17 event included presentations and interactive discussions with CEOs and key executives from a wide range of biotechnology, diagnostic, medical device, and healthcare information technology.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene (NASDAQ: CLNN) Participates in Top Investor Conferences to Showcase Lead Drug Candidate CNM-Au8
